MCDA Hemlibra® in haemophilia A with inhibitors

//MCDA Hemlibra® in haemophilia A with inhibitors

MCDA Hemlibra® in haemophilia A with inhibitors

Determining the value contribution of emicizumab (Hemlibra®) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis

Avaliable at: https://journals.sagepub.com/doi/full/10.1177/2284240319880534

2020-09-23T17:55:44+00:00October 8th, 2019|Articles|